Multiparametric MRI of early tumor response to immune checkpoint blockade in metastatic melanoma.
CTLA-4 antigen
biomarkers
immunotherapy
melanoma
translational medical research
tumor
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
accepted:
06
08
2021
entrez:
25
9
2021
pubmed:
26
9
2021
medline:
13
1
2022
Statut:
ppublish
Résumé
Immune checkpoint inhibitors are now standard of care treatment for many cancers. Treatment failure in metastatic melanoma is often due to tumor heterogeneity, which is not easily captured by conventional CT or tumor biopsy. The aim of this prospective study was to investigate early microstructural and functional changes within melanoma metastases following immune checkpoint blockade using multiparametric MRI. Fifteen treatment-naïve metastatic melanoma patients (total 27 measurable target lesions) were imaged at baseline and following 3 and 12 weeks of treatment on immune checkpoint inhibitors using: T Differential tumor growth kinetics in response to immune checkpoint blockade were measured in individual metastases within the same patient, demonstrating significant intertumoral heterogeneity in some patients. Early detection of tumor cell death or cell loss measured by a significant increase in the apparent diffusivity (D Multiparametric MRI demonstrated potential for early detection of successful response to immune checkpoint inhibitors in metastatic melanoma.
Sections du résumé
BACKGROUND
Immune checkpoint inhibitors are now standard of care treatment for many cancers. Treatment failure in metastatic melanoma is often due to tumor heterogeneity, which is not easily captured by conventional CT or tumor biopsy. The aim of this prospective study was to investigate early microstructural and functional changes within melanoma metastases following immune checkpoint blockade using multiparametric MRI.
METHODS
Fifteen treatment-naïve metastatic melanoma patients (total 27 measurable target lesions) were imaged at baseline and following 3 and 12 weeks of treatment on immune checkpoint inhibitors using: T
RESULTS
Differential tumor growth kinetics in response to immune checkpoint blockade were measured in individual metastases within the same patient, demonstrating significant intertumoral heterogeneity in some patients. Early detection of tumor cell death or cell loss measured by a significant increase in the apparent diffusivity (D
CONCLUSIONS
Multiparametric MRI demonstrated potential for early detection of successful response to immune checkpoint inhibitors in metastatic melanoma.
Identifiants
pubmed: 34561275
pii: jitc-2021-003125
doi: 10.1136/jitc-2021-003125
pmc: PMC8475139
pii:
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Cancer Research UK
ID : C19212/A16628
Pays : United Kingdom
Organisme : Cancer Research UK
ID : 16465
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C9685/A25177
Pays : United Kingdom
Organisme : Cancer Research UK
ID : 27150
Pays : United Kingdom
Organisme : Cancer Research UK
ID : 16628
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C19212/A911376
Pays : United Kingdom
Informations de copyright
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: No conflict of interest to declare with respect to the content of this work. AL, MS, LB, and J-ML are employees of AstraZeneca UK.
Références
Sci Rep. 2019 Dec 2;9(1):18069
pubmed: 31792256
Clin Cancer Res. 2009 Dec 1;15(23):7412-20
pubmed: 19934295
Acta Derm Venereol. 2020 Jun 3;100(11):adv00142
pubmed: 32346748
N Engl J Med. 2015 Jul 2;373(1):23-34
pubmed: 26027431
Science. 2018 Mar 23;359(6382):1350-1355
pubmed: 29567705
Br J Cancer. 2015 Apr 28;112(9):1471-9
pubmed: 25880014
Transl Oncol. 2017 Dec;10(6):956-975
pubmed: 29078205
Clin Cancer Res. 2012 Mar 1;18(5):1415-25
pubmed: 22235096
J Clin Oncol. 2015 Nov 1;33(31):3541-3
pubmed: 26261262
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Eur Radiol. 2018 Aug;28(8):3141-3150
pubmed: 29222677
Neoplasia. 2019 Oct;21(10):1036-1050
pubmed: 31521051
Sci Rep. 2019 Jul 24;9(1):10742
pubmed: 31341212
BMC Cancer. 2015 Nov 14;15:900
pubmed: 26573613
Br J Cancer. 2019 Oct;121(8):629-630
pubmed: 31527686
Lancet. 2017 Oct 21;390(10105):1853-1862
pubmed: 28822576
J Neurooncol. 2020 Jan;146(2):339-346
pubmed: 31873875
Cancer Chemother Pharmacol. 2013 Dec;72(6):1343-52
pubmed: 24141375
Br J Cancer. 2003 Apr 7;88(7):1135-42
pubmed: 12671716
Nat Commun. 2018 Nov 7;9(1):4664
pubmed: 30405135
Cancers (Basel). 2020 Nov 24;12(12):
pubmed: 33255267
Cancer Treat Rev. 2017 Sep;59:71-78
pubmed: 28756306
N Engl J Med. 2019 Oct 17;381(16):1535-1546
pubmed: 31562797
Clin Cancer Res. 2017 Aug 15;23(16):4671-4679
pubmed: 28592629
J Clin Oncol. 2006 Jul 10;24(20):3293-8
pubmed: 16829653
Nat Commun. 2020 Aug 27;11(1):4306
pubmed: 32855398
Curr Cardiol Rep. 2020 May 29;22(7):47
pubmed: 32472218
Nature. 2013 Sep 19;501(7467):355-64
pubmed: 24048068
Nat Med. 2018 Dec;24(12):1852-1858
pubmed: 30478423
NPJ Genom Med. 2017;2:
pubmed: 28819565
Front Oncol. 2018 Sep 10;8:367
pubmed: 30250827
Ann Oncol. 2018 Oct 1;29(10):2115-2120
pubmed: 30137228
Clin Cancer Res. 2019 Jun 15;25(12):3538-3547
pubmed: 30842125
J Nucl Med. 2020 Apr;61(4):512-519
pubmed: 31586002
Eur Radiol. 2017 Jul;27(7):2726-2736
pubmed: 27798751
J Mol Med (Berl). 2020 Feb;98(2):161-177
pubmed: 31970428
Magn Reson Med. 2020 Jun;83(6):2243-2252
pubmed: 31737935